Summit Therapeutics is trading 4.07% down at $13.43 after opening-market selling extended the August 13 decline.
- No reliable company-specific catalyst explaining the August 14 move was identified.
- The August 12 approval of ivonescimab in China was positive; funding-concern reporting dates to July 23.
- Broader indexes are essentially flat, providing little evidence of a market-wide driver.